FIELD: medicine.
SUBSTANCE: there is described a mucosal vaccine containing a medicinal antigen carrier representing a complex containing lung surfactant protein B or at least one fragment thereof, lung surfactant protein C or at least one fragment thereof, and at least one lipid, and an antigen, and specified mucosal vaccine induces therapeutically significant mucosal immunity.
EFFECT: invention allows inducing therapeutically significant mucosal immunity.
15 cl, 8 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MUCOSAL VACCINE | 2011 |
|
RU2570394C2 |
| MUCOSAL INFLUENZA VIRUS VACCINE AND METHOD FOR INFLUENZA PREVENTION | 2004 |
|
RU2390351C2 |
| SECRETORY IgA AND IgG ANTIBODY INDUCER | 2006 |
|
RU2440138C2 |
| IMMUNOGEN PEPTIDE AGAINST GROUP A STREPTOCOCCI | 2018 |
|
RU2775621C2 |
| MUCOSAL VACCINE FOR IMMUNE THERAPY OF DISEASES CAUSED BY HUMAN PAPILLOMA VIRUSES, AND RELATED THERAPY (VERSIONS) | 2008 |
|
RU2377305C1 |
| PHARMACEUTICAL COMPOSITION BASED ON PLGA FOR THE INDUCTION OF THE EFFECTIVE MUCOSAL IMMUNE RESPONSE | 2018 |
|
RU2742580C2 |
| INTRANASAL VACCINE INDUCING CELL-MEDIATED IMMUNITY | 2019 |
|
RU2796973C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ATTENUATED Streptococcus pneumoniae STRAINS, AND ITS APPLICATION | 2018 |
|
RU2772131C2 |
| HENDRA AND NIPAH VIRUS G GLYCOPROTEIN IMMUNOGENIC COMPOSITIONS | 2012 |
|
RU2681529C2 |
| COMPOSITIONS AND METHODS OF TREATING FUNGAL AND BACTERIAL PATHOGENS | 2014 |
|
RU2717306C2 |
